期刊文献+

新疆维族与汉族乳腺癌组织mTOR及其下游分子4EBP1和S6K1表达差异研究 被引量:1

Expression of mTOR and its downstream signal 4EBP1and S6K1 in Xinjiang Uygur and Han breast cancer patients
原文传递
导出
摘要 目的:探讨新疆维吾尔族和汉族乳腺癌组织中哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)及其下游分子4EBP1和S6K1的表达差异。方法:选取2005-03-01-2009-09-30新疆医科大学附属肿瘤医院的维吾尔族和汉族女性浸润性乳腺癌患者285例,使用免疫组化方法检测磷酸化mTOR及其下游分子4EBP1和S6K1的表达状况;分别选取2012-01-01-2012-06-30新疆医科大学附属肿瘤医院63例维、汉新鲜乳腺癌和癌旁组织样本,使用荧光定量RT-PCR法检测mTOR及其下游分子4EBP1和S6K1的mRNA表达状况。结果:免疫组化结果显示,维吾尔族和汉族p-mTOR在乳腺癌组织中的阳性表达率分别为77.1%和67.4%(P=0.067),在癌旁组织中的阳性表达率分别为57.6%和61.7%(P=0.485);p-4EBP1在癌组织中的阳性表达率分别为31.9%和20.0%(P=0.020),在乳腺癌旁组织中的阳性表达率分别是4.9%和12.1%(P=0.029);p-S6K1在癌组织中的阳性表达率分别为41.0%和43.3%(P=0.695),在乳腺癌旁组织中的阳性表达率分别为14.0%和22.7%,P=0.054;荧光定量RT-PCR结果显示,维、汉乳腺癌组织中mTOR mRNA相对定量结果差异有统计学意义,P=0.045;4EBP1和S6K1mRNA相对定量结果差异无统计学意义,P值分别为0.128和0.404。结论:mTOR信号通路中p-4EBP1的表达水平存在维、汉民族的差异,为研究维、汉不同民族之间乳腺癌差异及个体化治疗提供了进一步研究方向。mTOR及其下游分子mRNA表达水平与磷酸化蛋白的表达并不完全一致,提示蛋白表达的调控位点可能位于转录后水平。 OBJECTIVE:To discuss the expression of roTOR and its downstream molecular 4EBP1 and S6K1 in of Xinjiang Uygur and Han breast cancer patients. METHODS: Totally 285 cases of breast cancer patients,who were treated in Affiliated Tumor Hospital of Xinjiang Medical University from March 1,2005 to September 30,2009, were randomly selected to detect the expression of p-mTOR, p 4EBP1 and p-S6K1 using immunohistochemistry. Sixty-three cases of breast cancer and paracancerous tissue were reserved respectively to detect the mRNA expression using RT-PCR technology. RESULTS: Results from immunohistochemistry of uygur and Han showed that the positive p-mTOR were 77.1% and 67.4% in breast cancer(P=0. 067),57.6% and 61.7% in normal tissue (P=0. 485) ;p-4EBP1 were 31.9% and 20.0% (P=0. 020) in breast cancer,4.9% and 12. 1%(P=0. 029) in normal tissue;p-S6K1 were 41.0% and 43.3% in breast cancer (P=0. 695) ,14.0% and 22.7% in normal tissue(P=0. 054). There was statistical difference of p-mTOR mRNA expression between Uygur and Han (P=0. 045), whereas p-4EBP1 and p-S6K1 mRNA were not significantly different (P value were 0. 128 and 0. 404 respectively). CONCLUSIONS: The higher expression of p-4EBP1 in Uygur breast cancer tissue may provide a basis for the further research of finding the disparities between ethnic groups and individualized treat ment. The regulation of activated protein expression in mTOR signaling pathway may be post transcriptional,in respect of the disaccord of mRNA with activated protein expression.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第23期1788-1793,共6页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(30960376)
关键词 P-MTOR p-4EBP1 p-S6K1 乳腺肿瘤 病理学 新疆 维吾尔族 汉族 p-mTOR p-4EBP1 p-S6K1 breast neoplasms/pathology xinjiang Uygur nationality Han nationality
  • 相关文献

参考文献18

  • 1Jemal A,Bray F,Center MM,et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2) :69-90. 被引量:1
  • 2黄哲宙,陈万青,吴春晓,郑荣寿,陈建国,杨念念,王宁,张思维,郑莹.中国女性乳腺癌的发病和死亡现况——全国32个肿瘤登记点2003—2007年资料分析报告[J].肿瘤,2012,32(6):435-439. 被引量:369
  • 3徐雅莉,孙强,单广良,张瑾,廖海波,李世拥,姜军,邵志敏,蒋宏传,沈念春,石岳,尉承泽,张保宁,陈妍华,段学宁,李波.中国女性乳腺癌发病相关危险因素:病例对照研究[J].协和医学杂志,2011,2(1):7-14. 被引量:77
  • 4Lorusso PM. Mammalian target of rapamycin as a rational thera- peutic target for breast cancer treatment[J]. Oncology, 2013,84 (1) :43-56. 被引量:1
  • 5McAuliffe PF, Meric-Bernstam F, Mills GB, et al. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis[J]. Clin Breast Cancer,2010,10(Suppl 3) :59-65. 被引量:1
  • 6Kim EK,Kim HA,Koh JS,et al. Phosphorylated S6K1 is a possi- ble marker for endocrine therapy resistance in hormone receptor- positive breast cancer[J]. Breast Cancer Res Treat, 2011, 126 (1):93-99. 被引量:1
  • 7Remmele W, Stegner HE. Recommendation for uniform defini- tion of an immunoreactivc score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue [in German]. Pathologe, 1987,8(3) : 138-140. 被引量:1
  • 8Sato T, Nakashima A, Guo L, et al. Single amino-acid changes that confer constitutive activation of roTOR are discovered in hu- man cancer[J]. Oncogene, 2010,29 (16) : 2746-2752. 被引量:1
  • 9Montero JC,Chen X, Ocana A, et al. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells : therapeutic implications[J]. Mol Cancer Ther, 2012,11 (6) 1342-1352. 被引量:1
  • 10Ciuffreda L, Di Sanza C, Incani UC, et al. The mtor pathway: a new target in cancer therapy[J]. Curr Cancer Drug Targets, 2010,6 (5) : 484-495. 被引量:1

二级参考文献71

  • 1刘民锋,罗剑,余险峰,唐启彬,陈勇军,邹声泉.PTEN和mTOR信号转导通路在胆管癌发展中作用的研究[J].中国普通外科杂志,2006,15(4):274-276. 被引量:13
  • 2杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:278
  • 3Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J, 2004, 6(4): 589-604. 被引量:1
  • 4LiJ, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brainp breast and prostate cancer. Science, 1997, 275(5308): 1943-1947. 被引量:1
  • 5Steelman LS, B ertrrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets, 2004, 8(6): 537-550. 被引量:1
  • 6Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Can, 2006. 6(9): 729-734. 被引量:1
  • 7Shaw RJ, Canfley LC. Ras, PI(3)K and roTOR signalling controls turnout cell growth. Nature, 2006, 441 (7092): 424-430. 被引量:1
  • 8Massion PP, Taflan PM, Shyr Y, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med, 2004, 170(10): 1088-1094. 被引量:1
  • 9Conde E, Angulo B, Tang M, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res, 2006, 12(3): 710-717. 被引量:1
  • 10Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 1997, 275 (5300): 628-630. 被引量:1

共引文献479

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部